Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
Viking Therapeutics' stock soars 18% as data on oral weight-loss drug looms
Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings that showed enough cash on its balance sheet to fund key clinical trials.
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
Viking Therapeutics, Inc. (VKTX) Q3 2024 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2024 Earnings Conference Call October 23, 2024 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Joon Lee – Truist Annabel Samimy – Stifel Steve Seedhouse – Raymond James Roger Song – Jefferies Jay Olson – Oppenheimer Justin Zelin – BTIG Thomas Smith – Leerink Partners Yale Jen – Laidlaw & Company Hardik Parikh – JPMorgan Alex Ramsey – William Blair Operator Welcome to the Viking Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all parties are in a listen-only mode.
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) reachead $65.80 at the closing of the latest trading day, reflecting a +1.83% change compared to its last close.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Viking recently announced the results of an early-stage clinical trial for VK0214.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Where Will Viking Therapeutics Be in 5 Years?
We could be witnessing the birth of a major player in the biotech industry.
The Ultimate Biotech Stock to Buy With $100 Right Now
This company is operating in one of today's hottest markets.
